The ‘French exception’: the right to continuous deep sedation at the end of life by Horn, Ruth
204   Horn R. J Med Ethics 2018;44:204–205. doi:10.1136/medethics-2017-104484
The ‘French exception’: the right to continuous deep 
sedation at the end of life
Ruth Horn
Brief report
To cite: Horn R. J Med Ethics 
2018;44:204–205.
Oxford Big Data Institute, 
Wellcome Centre for Ethics and 
Humanities, Oxford, UK
Correspondence to
Dr Ruth Horn, Nuffield 
Department of Population 
Health, University of Oxford, 
Oxford Ox3 7LF, UK;  
 ruth. horn@ ethox. ox. ac. uk
Received 20 July 2017
Revised 20 September 2017
Accepted 3 October 2017
Published Online First 
22 October 2017
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In 2016, a law came into force in France granting 
terminally ill patients the right to continuous deep 
sedation (CDS) until death. This right was proposed as an 
alternative to euthanasia and presented as the ’French 
response’ to problems at the end of life. The law draws 
a distinction between CDS and euthanasia and other 
forms of sympton control at the end of life. France is the 
first country in the world to legislate on CDS . This short 
report describes the particular context and underlying 
social values that led to this piece of legislation, and 
explores its meaning in the wider French context.
In February 2016, a law was adopted in France 
granting terminally ill patients who refuse life-sus-
taining treatment (LST) the right to continuous deep 
sedation (CDS).1 The right to CDS was presented 
as the ‘French exception’ or the ‘French response’ 
to euthanasia. The expression ‘French exception’ 
is used in France to distinguish the country from 
other countries with regard to the relationship 
between the State and its social systems such as, 
culture, language or, as in this case, the healthcare 
system.2 The French republican model provides 
that the State regulates these systems in order to 
preserve society’s common values, or the ‘general 
will’, rather than individual interests as is the case in 
more liberal societies.3 What social values does the 
State seek to preserve with the ‘right to CDS’? In 
the following, I will describe the socio-legal context 
that gave rise to this law, and discuss the meaning of 
the law in the French context.
Since the late 1970s, the French end-of-life 
debate has been characterised by an asymmetry 
between physicians’ and patient rights. Although 
the paternalistic approach has been criticised in 
the public debate and several laws on patient rights 
have been adopted, respect for patient autonomy 
has struggled to find a place in French medical 
practice. A first attempt to strengthen patient rights 
was made in 2002 when a law was adopted that 
acknowledged, among others, the right to refuse 
treatment.4 However, in 2003, the case of Vincent 
Humbert, a paraplegic patient who claimed his right 
to die, highlighted the uncertainties of physicians 
regarding the legality of withdrawing LST, such as 
clinically assisted hydration and nutrition.5 This 
case attracted much media attention and generated 
an important parliamentary report in 2004.6 This 
report led to the adoption of the law ‘on patient 
rights and the end of life’ in 2005. Yet, the law did 
not, as the name could suggest, create a frame-
work to enhance patient rights. Rather, it reassured 
physicians about the legality to withdraw LST if 
they deem it necessary.5 7 8 Even though the law 
stipulated that patients ‘can refuse every treatment’, 
physicians were not required to accept their refusal. 
Rather the law stated that the physician should 
‘do all that is possible to convince the patient to 
continue the treatment when the refusal endangers 
the latter’s life’. Similarly, in case of incompetent 
patients, advance decisions to refuse treatment only 
had advisory value but were not legally binding.
Since the 2005 law came into force, a series of 
parliamentary reports have evaluated its relevance 
and highlighted persisting problems with regard to: 
pain control, respect for patient autonomy and deci-
sions to withdraw LSTs.9–12 Cases widely covered 
in the media, such as that of Hervé Pierra13 or 
Vincent Lambert,14 confirmed the need for further 
legal clarification. The first case revealed deficien-
cies in adequate pain management of a terminally 
ill patient who, following the withdrawal of his 
feeding tube, subsequently suffered from heavy 
seizures for over 6 days. The second case involves 
a patient in a minimally conscious state who has 
been kept alive since 2008 due to protracted liti-
gation engaged by his parents. The latter opposed 
to the withdrawal of LSTs initiated by the medical 
team in 2012 and, according to his wife, in agree-
ment with the patient’s precedent wishes. In 2015, 
the Lambert was taken to the European Court of 
Human Rights which decided in favour of treat-
ment withdrawal. The decision was backed by the 
Conseil d’Etat in 2017.14 Both cases demonstrate 
the absence of clear decisional procedures regarding 
the respect for patients' past beliefs and wishes 
that,at least until 2017, has characterised the legal 
landscape in France.
In 2015, in an attempt to address the insufficien-
cies of the law, the parliamentarians Alain Claeys 
and Jean Leonetti submitted a bill on ‘new rights 
for patients and terminally ill persons’.15 This 
bill sought to ensure that patients can refuse LST 
‘without having to suffer’ by giving them the right 
to  CDS until death. France thus became the first 
country to consider a right to CDS. According 
to international guidelines, this extreme form of 
sedation, which renders patients unconscious until 
death, should be used only under strict monitoring 
and as a last resort option to manage intractable 
terminal suffering.16 Claeys and Leonetti’s propo-
sition highlighted the concern that physicians could 
refuse to manage patients’ symptoms when LST is 
withdrawn. For many years, in France, the use of 
strong painkillers at the end of life was associated 
with euthanasia. As a result of this, many physicians 
were reluctant to use sedation and opiates at the 
end of life which in turn led to an extreme fear 
of terminal suffering among patients, healthcare 
professionals and the public.5 Yet, paradoxically, 
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this fear also led some physicians to use lethal cocktails of anal-
gesics with the intention to hasten patients’ death in order to 
efficiently terminate suffering.8 Consequently, when the 2015 
Bill was submitted for a first reading to the National Assembly, 
a large majority of parliamentarians saluted this proposition as 
a way to fulfil president François Hollande’s electoral promise 
of 2012 to introduce a law allowing the terminally ill ‘to benefit 
from medical assistance to end their lives with dignity’.17
Following further discussions, an amended version of the bill 
was adopted by the Senate and entered into force on 3 February 
2016. In the final version of the proposal, the right to CDS for 
any patient refusing LST has been limited to patients for whom 
death is imminent (up to 2 weeks) and pain is refractory (unman-
ageable by any other means). In addition, in cases where the 
terminally ill patient has lost capacity to express his/her will, the 
physician is now required to provide CDS when withdrawing 
LST.
Whether the law may be regarded as progressive in terms of 
assisted dying or criticised as opening the back door to eutha-
nasia, the proposed ‘French exception’ could be seen as first 
and foremost an expression of a lack of trust in French physi-
cians to effectively control pain at the end of life. The need to 
grant citizens a right to request the most extreme option of pain 
management is the result of doctors failing to fulfil their duty to 
sufficiently address patients’ pain and suffering. Some argue that 
the French decision to legislate on CDS, but not on euthanasia, 
marks the moral difference drawn between both practices.18 
The French law makes CDS a ‘sui generis end-of-life practice’ 
that can be requested by a patient under certain conditions.19 
CDS becomes herewith more than a medical response to severe 
pain. Moreover, by making it a requirement to provide CSD in 
every case where LST is withdrawn, CDS loses its purpose of 
controlling only refractory symptoms. As Raus et al18 state, there 
is no justification for always accompanying withdrawal of LST by 
CDS. The potential disproportionality of providing CDS where 
there is no medical need for such an important intervention 
with possible, although disputable, life-shortening effect,20 21 
raises ethical questions. It blurs the boundaries between CDS 
as a means to respond to refractory pain and CDS as a means 
to hasten death.22 Holm argues that CDS accompanied by the 
withdrawal of LST is very similar to euthanasia.23 Where this 
combination of practices is standard procedure, CDS needs to be 
carefully scrutinised to make it distinct from euthanasia, if this is 
what the French law intends.
In the French context, the blur of moral boundaries could 
result in two scenarios: (1) it could increase uncertainties and 
thus the reluctance of French physicians to use CDS, and there-
fore, physicians could avoid accepting patients’ wishes to with-
draw LST; (2) some physicians could use CDS as a means of 
performing euthanasia (depending on the amount of sedatives 
administered) but without being monitored, as is normally the 
case in countries that have adopted legislation on euthanasia.24 
The former is particularly problematic in the French context 
which is characterised by physicians’ attachment to provide treat-
ment at the end of life even where this is futile.5 8 Given these 
possible scenarios, it can be argued that rather than granting 
terminally ill patients the right to request CDS and requiring 
doctors to accompany the withdrawal of LST for incompe-
tent patients by CDS, French legislation should have aimed for 
improved pain management training and supporting guidelines 
on how and when to use CDS.
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